Non–Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence-Reference-Cited by-同舟云学术

Non–Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence

Published:2020-10-14 Issue:1 Volume:77 Page:11-21
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:

Author:

Patti Giuseppe,Haas Sylvia

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference93 articles.

1. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med.,2009

2. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N Engl J Med.,2013

3. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N Engl J Med.,2011

4. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med.,2011

5. Evidence-based development and rationale for once-daily rivaroxaban dosing regimens across multiple indications;Kubitza;Clin Appl Thromb Hemost.,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor Xa inhibitors versus warfarin in patients with non-valvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials;Annals of Medicine & Surgery;2024-01-03

2. Factors determining adherence to anticoagulant therapy in patients with atrial fibrillation;Russian Journal of Cardiology;2023-04-12

3. Cardiometabolic Guidelines: Cardiovascular Risk Assessment and Management in Patients with Dysglycemia;Dubai Diabetes and Endocrinology Journal;2023

4. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database;Advances in Therapy;2022-11-18

5. Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation;American Journal of Cardiovascular Drugs;2022-10-18